Response to PHARMAC on access to new medicines in New Zealand compared to Australia

New Zealand Medical Journal

Volumn 124, Issue 1347, 2011, Pages 18-

  Milne, Richard ^a   Wonder, Michael ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b Consultant Health Economist Sydney ^*  (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DABIGATRAN; HARKOSERIDE; HIRULOG; MODAFINIL; PARATHYROID HORMONE[1-34]; RALOXIFENE; ROSIGLITAZONE;

ACCESS TO INFORMATION; ANTICOAGULANT THERAPY; AUSTRALIA; BUDGET; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG COST; DRUG WITHDRAWAL; FUNDING; HEALTH CARE ACCESS; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HUMAN; INVESTMENT; NEW ZEALAND; NOTE; PERCUTANEOUS CORONARY INTERVENTION; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT;

EID: 84855841559     PISSN: None     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Note

References (4)

1. Wonder MJ, Milne RJ. Access to new medicines in New Zealand compared to Australia. New Zealand Medical Journal. 2011;124(1346). Epub Nov. 25. http://journal.nzma.org.nz:8080/journal/124-1346/4966/content.pdf
2. Moodie P, Metcalfe S, Poynton M. Do pharmaceutical score cards give us the answers we seek? N Z Med J. 2011;124(1346). http://journal.nzma.org.nz/journal/124-1346/4976/content.pdf
3. Grocott R. Applying Programme Budgeting Marginal Analysis in the health sector: 12 years of experience. Expert rev. 2009;9(2):181-7.
4. Harris AH, Hill SR, Chin G, Li JJ, Walkom E. The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004. Med Decis Making. 2008;28(5):713-22